Browsing Tag
Emalex Biosciences
2 posts
Teva gets Priority Review for ecopipam just months after buying Emalex for $700m
Teva has secured FDA Priority Review for ecopipam in pediatric Tourette syndrome, putting a late first-quarter 2027 decision date on the key asset acquired through its $700 million purchase of Emalex Biosciences.
Ecopipam Priority Review puts Teva’s $700m Tourette bet on a Q1 2027 FDA clock
Ecopipam gets FDA Priority Review, putting Teva’s $700m Tourette acquisition on a late-Q1 2027 decision clock after positive Phase 3 data.